$3.95
1.19% today
NYSE, Feb 05, 04:21 pm CET
ISIN
US36870H1032
Symbol
GNLX
Sector
Industry

Genelux Stock price

$3.90
+1.36 53.54% 1M
+2.28 140.74% 6M
+1.54 65.25% YTD
-4.67 54.49% 1Y
-2.10 35.00% 3Y
-2.10 35.00% 5Y
-2.10 35.00% 10Y
NYSE, Closing price Tue, Feb 04 2025
+0.37 10.48%
ISIN
US36870H1032
Symbol
GNLX
Sector
Industry

Key metrics

Market capitalization $134.70m
Enterprise Value $102.68m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 10,268.00
P/S ratio (TTM) P/S ratio 13,470.00
P/B ratio (TTM) P/B ratio 4.07
Revenue growth (TTM) Revenue growth -96.64%
Revenue (TTM) Revenue $10.00k
EBIT (operating result TTM) EBIT $-28.95m
Free Cash Flow (TTM) Free Cash Flow $-24.36m
Cash position $34.06m
EPS (TTM) EPS $-0.95
P/E forward negative
P/S forward 28,062.50
EV/Sales forward 21,391.67
Short interest 4.92%
Show more

Is Genelux a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Genelux Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Genelux forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Genelux forecast:

Buy
100%

Financial data from Genelux

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.01 0.01
96% 96%
100%
- Direct Costs 0.88 0.88
17% 17%
8,800%
-0.87 -0.87
6% 6%
-8,700%
- Selling and Administrative Expenses 11 11
45% 45%
105,700%
- Research and Development Expense 17 17
50% 50%
166,400%
-28 -28
46% 46%
-280,700%
- Depreciation and Amortization 0.88 0.88
17% 17%
8,800%
EBIT (Operating Income) EBIT -29 -29
43% 43%
-289,490%
Net Profit -28 -28
11% 11%
-276,600%

In millions USD.

Don't miss a Thing! We will send you all news about Genelux directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genelux Stock News

Neutral
GlobeNewsWire
2 days ago
WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025.
Neutral
GlobeNewsWire
about 2 months ago
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024.
Neutral
GlobeNewsWire
3 months ago
WESTLAKE VILLAGE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference, taking pl...
More Genelux News

Company Profile

Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.

Head office United States
CEO Thomas Zindrick
Employees 23
Founded 2001
Website www.genelux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today